Arvinas amends Yale license, pays $14.95M upfront, $5M in 2025, eliminates minimum royalties

ARVINAS, INC.

Upfront $14.95M to Yale for amended license and collaboration income from Novartis deal on ARV-766 and AR-V7.
Additional $5M payment due on first anniversary (June 2025).
Contingent milestones up to $15M for approval of first two royalty products.
Ongoing low single-digit royalties on collaboration products; lower single-digit on meaningfully involved products.
Minimum annual royalties and annual fees eliminated; Yale releases all prior claims.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.